Preventive Intervention Value of Inclisiran Combined With DCB in Vulnerable Coronary Atherosclerotic Plaques

Minimum luminal area

The PASSIVATE-CAP study is an investigator-initiated, prospective, randomized, multicenter,
 open-label superiority trial focusing on acute coronary syndrome (ACS) patients with
 nonflow-limiting vulnerable plaques in nonculprit vessels. In this study, eligible patients
 were randomized at a 1:1 ratio into two groups: patients who received guideline-directed
 medical therapy (GDMT) and patients who received GDMT combined with a drug-coated balloon
 (DCB). In this study, the use of PCSK9 inhibitors was limited to inclisiran. The primary
 endpoint was the minimal lumen area of the target lesion 1 year after randomization. The
 secondary endpoints encompass a range of factors, including the proportion of patients with
 vulnerable plaques in the target vessel, fibrous cap thickness, lipid core arc of the target
 lesion, minimal lumen area of the target vessel, and extent of LDL-C reduction in patients
 treated with inclisiran.